Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Toshihiro InabaShun Ishibashi

Abstract

Fibrates, peroxisome proliferator-activated receptor a agonists, are widely used as lipid-lowering agents with anti-atherogenic activity. However, conflicting results have been reported with regard to their pharmacological effects on plasma lipoprotein profiles as well as on atherosclerosis in animal models. Furthermore, the anti-atherogenic effects of bezafibrate, one of the most commonly used fibrates, in animal models have not been reported. In the present study, we investigated the effects of bezafibrate on lipoprotein profiles as well as on atherosclerosis in low-density lipoprotein receptor knockout (LDLR-/-) mice fed an atherogenic diet for 8 weeks. Bezafibrate decreased plasma levels of both cholesterol and triglycerides (TG), while increasing plasma levels of high-density lipoprotein-cholesterol (HDL-C). Since hepatic TG production was significantly reduced in the bezafibrate-treated mice lacking LDLR, the plasma lipid-lowering effects of bezafibrate might be primarily mediated by the suppression of hepatic production of apolipoprotein-B-containing lipoproteins. In parallel with the reduced ratio of non-HDL-C to HDL-C, bezafibrate suppressed fatty streak lesions in the aortic sinus by 51%. To determine whether or not b...Continue Reading

References

Dec 1, 1987·Atherosclerosis·B PaigenR A Williams
Feb 1, 1985·The Journal of Clinical Investigation·C S WangP Alaupovic
Jan 1, 1983·European Journal of Clinical Pharmacology·F Heller, C Harvengt
May 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M J CaslakeJ Shepherd
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·M ShimadaN Yamada
Aug 7, 1998·Atherosclerosis·B Staels, J Auwerx
Nov 10, 1998·Circulation·B StaelsJ C Fruchart
Feb 17, 1999·Photodermatology, Photoimmunology & Photomedicine·T R CovenJ G Krueger
Feb 26, 2000·Journal of Medicinal Chemistry·T M WillsonB R Henke
May 29, 2000·The Journal of Biological Chemistry·M Guerre-MilloB Staels
Jul 6, 2000·Circulation·UNKNOWN Bezafibrate Infarction Prevention (BIP) study
Apr 18, 2001·The Journal of Clinical Investigation·K TordjmanC F Semenkovich
Jan 31, 2002·Annual Review of Medicine·Joel Berger, David E Moller
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Oct 16, 2002·The Journal of Biological Chemistry·Hélène DuezBart Staels
Nov 15, 2002·The Journal of Biological Chemistry·Toshimasa YamauchiTakashi Kadowaki
Nov 27, 2002·Circulation·Yoshihisa OkamotoYuji Matsuzawa
May 8, 2003·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Jong Il KimMitsuhiro Yokoyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.